» Articles » PMID: 33310142

WHO HEARTS: A Global Program to Reduce Cardiovascular Disease Burden: Experience Implementing in the Americas and Opportunities in Canada

Overview
Journal Can J Cardiol
Publisher Elsevier
Date 2020 Dec 14
PMID 33310142
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Globally, cardiovascular diseases (CVDs) are the leading cause of death. Viewed as a threat to the global economy, the United Nations included reducing noncommunicable diseases, including CVDs, in the 2030 sustainable development goals, and the World Health Assembly agreed to a target to reduce noncommunicable diseases 25% by the year 2025. In response, the World Health Organisation led the development of HEARTS, a technical package to guide governments in strengthening primary care to reduce CVDs. HEARTS recommends a public health and health system approach to introduce highly simplified interventions done systematically at a primary health care level and has a focus on hypertension as a clinical entry point. The HEARTS modules include healthy lifestyle counselling, evidence-based treatment protocols, access to essential medicines and technology, CVD risk-based management, team-based care, systems for monitoring, and an implementation guide. There are early positive global experiences in implementing HEARTS. Led by the Pan American Health Organisation, many national governments in the Americas are adopting HEARTS and have shown early success. Unfortunately, in Canada hypertension control is declining in women since 2010-2011 and the dramatic reductions in rates of CVD seen before 2010 have flattened when age adjusted and increased for rates that are not age adjusted, and there are marked increases in absolute numbers of Canadians with adverse CVD outcomes. Several steps that Canada could take to enhance hypertension control are outlined, the core of which is to implement a strong governmental nongovernmental collaborative strategy to prevent and control CVDs, focusing on HEARTS.

Citing Articles

Global, regional, and national epidemiology of ischemic heart disease among individuals aged 55 and above from 1990 to 2021: a cross-sectional study.

Xue P, Lin L, Li P, Cheng S, Chen D, Fan M BMC Public Health. 2025; 25(1):985.

PMID: 40075403 PMC: 11905664. DOI: 10.1186/s12889-025-22193-6.


Comprehensive analysis of non-coding RNA-mediated endothelial cell-specific regulatory circuits in coronary artery disease risk.

Huang B, Lai Z, Wang X, Zhang Q, Hu T, Yu F Front Genet. 2025; 16:1559798.

PMID: 40061128 PMC: 11886895. DOI: 10.3389/fgene.2025.1559798.


Cardiovascular disease in the Americas: the epidemiology of cardiovascular disease and its risk factors.

Joseph P, Lanas F, Roth G, Lopez-Jaramillo P, Lonn E, Miller V Lancet Reg Health Am. 2025; 42:100960.

PMID: 40034110 PMC: 11873637. DOI: 10.1016/j.lana.2024.100960.


Patient-Physician Language Concordance and Cardiovascular Outcomes Among Patients With Hypertension.

Reaume M, Labossiere M, Batista R, Van Haute S, Tangri N, Rigatto C JAMA Netw Open. 2025; 8(2):e2460551.

PMID: 39969882 PMC: 11840650. DOI: 10.1001/jamanetworkopen.2024.60551.


Cardiomyocyte proliferation: Advances and insights in macrophage-targeted therapy for myocardial injury.

Wang T, Wang X, Ren W, Sun Z, Zhang Y, Wu N Genes Dis. 2025; 12(3):101332.

PMID: 39935606 PMC: 11810708. DOI: 10.1016/j.gendis.2024.101332.